Trial Profile
Inhaled pirfenidone (GP-101) in patients with idiopathic pulmonary fibrosis
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2014
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Avalyn Pharma
- 17 Sep 2014 New trial record
- 05 Aug 2014 Genoa Pharmaceuticals is planning to initiate this trial in early 2015, according to a media release.